The clinical significance of cereblon expression in multiple myeloma

被引：91

作者：

Schuster, Steven R. ^{[1
]}

Kortuem, K. Martin ^{[2
]}

Zhu, Yuan Xiao ^{[2
]}

Braggio, Esteban

Shi, Chang Xin ^{[2
]}

Bruins, Laura A. ^{[2
]}

Schmidt, Jessica E. ^{[2
]}

Ahmann, Greg ^{[2
]}

Kumar, Shaji ^{[3
]}

Rajkumar, S. Vincent ^{[3
]}

Mikhael, Joseph ^{[2
]}

LaPlant, Betsy

Champion, Mia D. ^{[2
]}

Laumann, Kristina

Barlogie, Bart

Fonseca, Rafael ^{[2
]}

Bergsagel, P. Leif ^{[2
]}

Lacy, Martha

Stewart, A. Keith ^{[2
]}

机构：

[1] Univ Colorado Hlth, Ft Collins, CO 80524 USA

[2] Mayo Clin Arizona, Div Hematol, Scottsdale, AZ USA

[3] Mayo Clin, Div Hematol, Rochester, MN USA

来源：

LEUKEMIA RESEARCH | 2014年 / 38卷 / 01期

关键词：

Multiple myeloma; Cereblon; Gene expression profiling; Immunomodulatory drugs; Biological markers; LENALIDOMIDE; THALIDOMIDE;

D O I：

10.1016/j.leukres.2013.08.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cereblon (CRBN) mediates immunomodulatory drug (IMiD) action in multiple myeloma (MM). We demonstrate here that no patient with very low CRBN expression responded to IMiD plus dexamethasone therapy. In 53 refractory MM patients treated with pomalidomide and dexamethasone, CRBN levels predict for decreased response rates and significant differences in PFS (3.0 vs. 8.9 months, p<0.001) and OS (9.1 vs. 27.2 months, p=0.01) (lowest quartile vs. highest three quartiles). While higher CRBN levels can serve as a surrogate for low risk disease, our study demonstrates that low CRBN expression can predict resistance to IMiD monotherapy and is a predictive biomarker for survival outcomes. (C) 2013 Elsevier Ltd. All rights reserved.

引用

收藏

页码：23 / 28

页数：6

相关论文

共 24 条

[1] Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma [J].

Bergsagel, PL ;

Kuehl, WM ;

Zhan, FH ;

Sawyer, J ;

Barlogie, B ;

Shaughnessy, J .

BLOOD, 2005, 106 (01) :296-303

[2] High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance [J].

Broyl, Annemiek ;

Kuiper, Rowan ;

van Duin, Mark ;

van der Holt, Bronno ;

el Jarari, Laila ;

Bertsch, Uta ;

Zweegman, Sonja ;

Buijs, Arjan ;

Hose, Dirk ;

Lokhorst, Henk M. ;

Goldschmidt, Hartmut ;

Sonneveld, Pieter .

BLOOD, 2013, 121 (04) :624-627

[3] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[4]

Egan J., 2012, ASH Annual Meeting Abstracts, V120, P3968

[5] Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism [J].

Escoubet-Lozach, Laure ;

Lin, I-Lin ;

Jensen-Pergakes, Kristen ;

Brady, Helen A. ;

Gandhi, Anita K. ;

Schafer, Peter H. ;

Muller, George W. ;

Worland, Peter J. ;

Chan, Kyle W. H. ;

Verhelle, Dominique .

CANCER RESEARCH, 2009, 69 (18) :7347-7356

[6] The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma [J].

Fonseca, R ;

Debes-Marun, CS ;

Picken, EB ;

Dewald, GW ;

Bryant, SC ;

Winkler, JM ;

Blood, E ;

Oken, MM ;

Santana-Dávila, R ;

González-Paz, N ;

Kyle, RA ;

Gertz, MA ;

Dispenzieri, A ;

Lacy, MQ ;

Greipp, PR .

BLOOD, 2003, 102 (07) :2562-2567

[7] High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone [J].

Heintel, Daniel ;

Rocci, Alberto ;

Ludwig, Heinz ;

Bolomsky, Arnold ;

Caltagirone, Simona ;

Schreder, Martin ;

Pfeifer, Sabine ;

Gisslinger, Heinz ;

Zojer, Niklas ;

Jaeger, Ulrich ;

Palumbo, Antonio .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (05) :695-700

[8] Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like Than in Germinal Center B-Cell-Like Phenotype [J].

Hernandez-Ilizaliturri, Francisco J. ;

Deeb, George ;

Zinzani, Pier L. ;

Pileri, Stefano A. ;

Malik, Farhana ;

Macon, William R. ;

Goy, Andre ;

Witzig, Thomas E. ;

Czuczman, Myron S. .

CANCER, 2011, 117 (22) :5058-5066

[9] Identification of a Primary Target of Thalidomide Teratogenicity [J].

Ito, Takumi ;

Ando, Hideki ;

Suzuki, Takayuki ;

Ogura, Toshihiko ;

Hotta, Kentaro ;

Imamura, Yoshimasa ;

Yamaguchi, Yuki ;

Handa, Hiroshi .

SCIENCE, 2010, 327 (5971) :1345-1350

[10] Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma [J].

Kyle, R. A. ;

Rajkumar, S. V. .

LEUKEMIA, 2009, 23 (01) :3-9